SCHEDULE: Sturm Ruger Rejects Beretta's $44.80 Tender Offer

Sturm Ruger & Co. Inc. rejected Beretta Holding S.A.'s request for a poison pill exemption, obstructing a premium all-cash tender offer for additional shares.

Summary

• Beretta Holding S.A. sought an exemption from Sturm Ruger & Co. Inc.'s "poison pill" rights plan to proceed with a tender offer.
• Sturm Ruger's Board of Directors rejected this request on March 28, 2026.
• Beretta proposed an all-cash premium tender offer of $44.80 per share for up to 20.05% of Sturm Ruger's outstanding shares not already owned by Beretta.
• The $44.80 offer price represents a significant premium of approximately 20% over the 60-trading day volume-weighted average price ending March 24, 2026.
• Beretta expressed deep dismay at the Board's decision, viewing it as an obstruction to a premium cash tender offer for shareholders.
• Beretta's counsel conveyed significant concerns and skepticism regarding the sincerity of the Board's purported willingness to engage.
• Beretta is actively assessing all litigation options against Sturm Ruger's Board and its members.
• An in-person meeting between Beretta and Sturm Ruger has been scheduled for April 9, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for Sturm Ruger shareholders due to the rejection of a premium offer and the potential for costly litigation, creating significant uncertainty.

Positives

• Beretta's proposed tender offer of $44.80 per share represents a significant premium of approximately 20% to the volume-weighted average price of Sturm Ruger's shares over the 60 trading days ending March 24, 2026, which would benefit tendering shareholders.

Negatives

• Sturm Ruger's Board of Directors rejected Beretta's request for an exemption from its "poison pill" rights plan, obstructing a premium all-cash tender offer.
• Beretta expressed deep dismay and skepticism regarding the Board's sincerity in engaging, despite proposing a meeting.
• The Board's action prevents shareholders from immediately realizing a 20% premium on a portion of their shares.

Risks

• Beretta Holding S.A. is actively assessing all litigation options against Sturm Ruger's Board of Directors and its members, which could lead to costly and time-consuming legal proceedings for the Issuer.
• The continued use of the "poison pill" rights plan by Sturm Ruger could deter other potential acquirers and limit shareholder value realization.

Future Outlook

Beretta Holding S.A. is actively assessing all litigation options against Sturm Ruger's Board and its members following the rejection of its tender offer exemption. An in-person meeting between the parties is scheduled for April 9, 2026, to discuss the situation further.

Management Comments

• Beretta Holding S.A. expressed deep dismay that the Issuer's Board of Directors chose to reject the request for a waiver to the poison pill, and therefore obstruct Beretta from proceeding with its cash tender offer to the Issuer's shareholders at a premium.
• Beretta's counsel expressed significant concerns and skepticism regarding the sincerity of the Board's purported 'willingness to engage.'
• Beretta is actively assessing all litigation options against the Board and its members.

Industry Context

StockSavvy.ai notes that the use of a 'poison pill' defense is a common tactic employed by target companies to fend off unsolicited takeover attempts, often raising questions about corporate governance and the board's commitment to maximizing shareholder value. While intended to protect the company from opportunistic bids, such actions can sometimes be perceived as entrenching management and preventing shareholders from accepting premium offers. This situation highlights the ongoing tension between a board's fiduciary duties and a significant shareholder's desire to increase its stake at a premium.

Comparison to Industry Standards

• Poison pill defenses, while legal, are often viewed critically by institutional investors and shareholder rights advocates as they can prevent shareholders from realizing a control premium.
• The rejection of a 20% premium offer, without clear alternative value-enhancing strategies, can be seen as prioritizing board control over immediate shareholder returns, a stance that has historically led to shareholder activism or litigation in similar situations across various industries.

Corporate Governance

Legal Proceedings

• Beretta Holding S.A. is actively assessing all litigation options against Sturm Ruger's Board of Directors and its members following the rejection of its poison pill exemption request.

Stakeholder Impact

• Shareholders: Denied the opportunity to tender shares at a significant 20% premium, potentially leading to frustration and reduced confidence in the Board.
• Board of Directors: Faces potential litigation from Beretta Holding S.A. and scrutiny regarding its decision to reject a premium offer using a poison pill defense.
• Beretta Holding S.A.: Its strategic acquisition efforts are obstructed, leading to potential legal action and increased costs.

Next Steps

• An in-person meeting between Beretta Holding S.A. and Sturm Ruger & Co. Inc. is scheduled for April 9, 2026.
• Beretta Holding S.A. is actively assessing all litigation options against Sturm Ruger's Board of Directors and its members.

Key Dates

Recommendation

The situation presents significant uncertainty. While the rejection of a premium offer is negative for immediate shareholder value, the ongoing dialogue and potential litigation introduce volatility. Investors should hold to monitor the outcome of the April 9th meeting and the assessment of litigation options, as these events could significantly impact the stock's trajectory.

Keywords

Sturm Ruger, Beretta Holding, Tender Offer, Poison Pill, Shareholder Rights, Acquisition, Litigation, Corporate Governance, Premium Offer, Firearms Industry